TRANSDERMAL DELIVERY OF BUPRENORPHINE THROUGH CADAVER SKIN

被引:34
作者
ROY, SD [1 ]
ROOS, E [1 ]
SHARMA, K [1 ]
机构
[1] CYGNUS THERAPEUT SYST,REDWOOD CITY,CA 94306
关键词
D O I
10.1002/jps.2600830204
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The skin permeation of buprenorphine base and HCI salt through cadaver skin was investigated. The octanol-water partition coefficient and solubilities of both buprenorphine free base and HCI salt were determined at 32 degrees C. As expected, buprenorphine free base was more lipophilic than its HCI salt and was practically insoluble in aqueous buffer at pH 8.7. The drug solubility decreased exponentially as the pH of the solution increased, whereas the permeability coefficient increased as the donor solution pH decreased. The skin flux of buprenorphine.HCI was significantly higher than that of the free base from propylene glycol/lauric acid vehicle mixtures. Buprenorphine base permeation through tape-stripped epidermis suggested that in addition to stratum corneum, viable epidermis presented a significant diffusion barrier because of the very low aqueous solubility of the free base observed. The mean steady-state skin flues of buprenorphine HCI were 20.3 and 29.7 mu g/cm(2)/h from propylene glycol:lauryl alcohol:ethanol (80:15:5) and propylene glycol:propylene glycol monolaurate:water (80:15:5) vehicle mixtures, respectively. The skin flux of buprenorphine HCI from various monolithic matrix patches was also evaluated. When capric acid, lauric acid, and lauryl alcohol were separately incorporated into an adhesive matrix, the skin flux of buprenorphine HCI was enhanced by a factor of 2 to 3.5. Finally, based on the total body clearance and minimum effective concentration of buprenorphine, a transdermal delivery rate of 2.5 mu g/cm(2)/h from a 20-cm(2) patch was estimated. The in vitro skin permeation data clearly suggest that transdermal delivery of buprenorphine is feasible to achieve a desired systemic analgesic effect.
引用
收藏
页码:126 / 130
页数:5
相关论文
共 12 条
[1]   SUB-LINGUAL BUPRENORPHINE USED POSTOPERATIVELY - 10-HOUR PLASMA DRUG CONCENTRATION ANALYSIS [J].
BULLINGHAM, RES ;
MCQUAY, HJ ;
PORTER, EJB ;
ALLEN, MC ;
MOORE, RA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (05) :665-673
[2]  
Cleary GW, 1990, USA patent, Patent No. 4906463
[3]  
DOBKIN A, 1977, CAN ANAESTH SOC J, V24, P166
[4]   BUPRENORPHINE - NEW POTENT LONG-ACTING SYNTHETIC ANALGESIC - COMPARISON WITH MORPHINE [J].
DOWNING, JW ;
LEARY, WP ;
WHITE, ES .
BRITISH JOURNAL OF ANAESTHESIA, 1977, 49 (03) :251-255
[5]  
FOLEY KM, 1986, ADV PAIN RES THER, V8, P117
[6]   PHARMACOKINETICS OF MORPHINE AND ITS SURROGATES .6. BIOANALYSIS, SOLVOLYSIS KINETICS, SOLUBILITY, PK'A VALUES, AND PROTEIN-BINDING OF BUPRENORPHINE [J].
GARRETT, ER ;
CHANDRAN, VR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (05) :515-524
[7]  
JANSINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P601
[8]  
JORGENSEN BC, 1988, CLIN J PAIN, V4, P75
[9]  
KOU JH, 1993, J PHARM RES, V10, P986
[10]   TRANSDERMAL DELIVERY OF NARCOTIC ANALGESICS - COMPARATIVE PERMEABILITIES OF NARCOTIC ANALGESICS THROUGH HUMAN CADAVER SKIN [J].
ROY, SD ;
FLYNN, GL .
PHARMACEUTICAL RESEARCH, 1989, 6 (10) :825-832